CORRECTION

Correction to: The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia

Valeria Santini · Michael Lübbert · Agnieszka Wierzbowska ·
Gert J. Ossenkoppele

Published online: February 15, 2022
© Springer Healthcare Ltd., part of Springer Nature 2022

Correction to: Adv Ther
<https://doi.org/10.1007/s12325-021-01948-8>

In the original article, a few errors have been identified and subsequently rectified.

In the abstract the incorrect phrase “and limiting the transcription of tumor suppressor genes, leading to gene silencing” has now been corrected to “and leading amongst others to re-expression of silenced tumor suppressor genes.”

In the key summary points, it has been specified that decitabine is indicated in the European Union (EU).

In Table 2 data are erroneous due to a misprint. Total TC for anemia has now been corrected from (925) to (25), total TC for febrile neutropenia has been amended from (922) to (22), and total TC for Pyrexia has been amended from (200) to (8).

Further updates have been made to improve clarity of sentences but no amendment to the scientific content was made.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s12325-021-01948-8>.

V. Santini (✉)
Department of Experimental and Clinical Medicine,
MDS Unit, AOUC- University of Florence, Florence,
Italy
e-mail: valeria.santini@unifi.it

M. Lübbert
Department of Internal Medicine I, Medical Center,
University of Freiburg, Faculty of Medicine,
University of Freiburg Medical Center, Freiburg,
Germany

A. Wierzbowska
Department of Hematology, Medical University of
Lodz, Lodz, Poland

G. J. Ossenkoppele
Department of Haematology, Location VU
University Medical Center, Amsterdam,
The Netherlands